Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;56(7):3977-80.
doi: 10.1128/AAC.00260-12. Epub 2012 Apr 16.

Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada

Christopher F Lowe  1 , Allison McGeer, Matthew P Muller, Kevin Katz; Toronto ESBL Working Group
Affiliations

Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada

Christopher F Lowe et al. Antimicrob Agents Chemother. 2012 Jul.

Abstract

Retrospective review from 11 Canadian hospitals showed increasing incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae from 0.12 per 1,000 inpatient days during 2005 to 0.47 per 1,000 inpatient days during 2009. By 2009, susceptibility rates of ESBL-positive E. coli/K. pneumoniae were as follows: ciprofloxacin, 12.8%/9.0%; TMP/SMX, 32.9%/12.2%; and nitrofurantoin, 83.8%/10.3%. Nosocomial and nonnosocomial ESBL-producing E. coli isolates had similar susceptibility profiles, while nonnosocomial ESBL-producing K. pneumoniae was associated with decreased ciprofloxacin (P = 0.03) and nitrofurantoin (P < 0.001) susceptibilities.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Overall (solid lines) and nosocomial (dashed lines) incidence of ESBL-E clinical isolates between 2005 and 2009. Black, E. coli; gray, K. pneumoniae.
Fig 2
Fig 2
Susceptibility profile of ESBL-producing E. coli recovered over a 5-year period.
Fig 3
Fig 3
Susceptibility profile of ESBL-producing K. pneumoniae recovered over a 5-year period.
See this image and copyright information in PMC

References

    1. Clinical and Laboratory Standards Institute 2009. Performance standards for antimicrobial susceptibility testing. CLSI M100-S19. Clinical Laboratory Standards Institute, Wayne, PA
    1. Coque TM, et al. 2008. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg. Infect. Dis. 14:195–200 - PMC - PubMed
    1. Grundmann H, et al. 2010. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 15:19711. - PubMed
    1. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. 2010. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int. J. Antimicrob. Agents 36:293–294 - PubMed
    1. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. 2010. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn. Microbiol. Infect. Dis. 66:78–86 - PubMed

MeSH terms

LinkOut - more resources